Firefox about:blank D¢w$*n En￿or*I0." &4D25F3W3Es47￿A29A-9￿￿28F72822 Annual repon 2311212024 ANTIVE"NOM ANNUAL REPORT 2024 DETAILS Antivenom Foundation Period start Period end Reg: 1204543 3110812D23 2311212024 INTR()DUCTIC)N Over 6bn people tive wth venomous snakes and with ever increasing levels of deforestation 8nd encroachrnent into their natural habrtat. snakebites are inemtable. Everyyear 5 milb.on people are birren by venomous snakes. resulting in 80.(KK)-140.000 deaihs. and leaving 400,000 wiih life changing disabilities Including ampurations and organ failure. Snakebite Is a lact ol life lor rural and Indigenous communilies and is an occuparional hazard lor the farmers who grow our collee, chocolate and other commoditie5 we consume every day. Because the popuLation m05t affected are young 15-40 years old) and the consequences are severe. the impact of snakebite is disproportionate. wth 8 Combined burden of 6-8 milbon disabibty adjusted life years IDALYSI lost. This is a toll comparableto diseasessuch as prosiaiecancer. cemcal cancer. rheumatoid anhritis. viral hepatitis an¢J upper respiratorytract infections. The tragedy is that tre8tments for snakebite e￿st and are highlyeffective. Aniwenom prevents over 90% of morbidity and morrality and is lisieo as an esseniial medicine by iheWHO. bui the supply is in crisis. Less than 30% of the antNenorn needed is produced. and 40% of species have no specific treatrnent. These problerns ale concentrated in low- and middle-income countries where the import of fake or inappropriate antwenoms means that in some cases up to 90% of the available aniivenom is known not rowork. The Antivenom Foundation is a stan-up charity a big ambition.. to creaie the worlds. first international antwenorn stockpile. In doing so we hope to enable access io effectwe a￿tr￿e￿orn8 rhrough procuremeni mechanisms from vetted suppliers, with wrap around supporr from our exrenswe global new￿rk of ¢xperr volunteers. OBJECTIVES AND ACTIIIITIES Summan" of charin" purpose The primary aim of the AntNenom Foundation is to establish the world's first international antivenorn stockpile mechanism to pro￿lde effectwe treatments that prevent death and disability from the biles and stings of venomous animaLs. In pursuit of this primary g081 the Antivenom Foundaiion has scope to provide support io patients, physicians and local orgnisations. and to further research. education and awareness on the issue of animal envenomations. lof4 2411212024. 14:22 Firefox about:blank D¢w$*n En￿or*I0." &4D25F3W3Es47￿A29A-9￿￿28F72822 Annual repon 2311212024 ANTIVE"NOM Summan" of main acrivirics The goal of the Antwenorn foundation is incredibty ambitious and the trustees are under no illusions as to the long and hard road ahead. In this firstyearof actmty the trustees have focused on setting up the charity and connectinEWlth experts and community leaders. Due to the international outlook of the charty. we faced significant difficulties in opening a bank account and registering for gtrt aid. Thevery lengthy delays and uncertaintywe experienced on this front imp8ired fundraising activity duringthe period. The trLJStees applied io several small grant schemes, however, as a start-up charitywilh an internaiional outlook It has become clear Ihai there do noi appear to be any seed funding schemes in ihe UK ihar are wlling to take a risk with such an earty-stage initiatwe. Goingforwaid the antNenom foundation is goingto focus on rai51ng funds from donations to enable the first proof of concept delwery project. Despite the challenges on the set-up and fundraising side. the Antivenom Foundation has had some success through our ￿e￿Ork of expert volunre¢rs who have had a direct impaci on rhe ground (see achievemenis and performance). Stitement on Chirin. commission guidince on public benefir The Trusiees confirm that, in exercising their powers and duries. Ihey have had due regard 10 ihe guidance on public benefit issued bythe Charitycommission for England and Wales. The Trusiees are satisfied that the charity's actiwties hève been cairied out in a mannei that aligns wth the public benefit requirernent set out In the Charitycommission's guideb"nes. In makingdecisions, the Trustees have considered ￿th the aims and the actmfies of the charity. ensuring thai they are forthe public benefii and Ihat the chaiitys resources are used ettectivelyto further its charitable purposes. ACHIEVETrIENTS AND PERFORIIANCE Summati. of main achicvcmcnis Our main achievements in ihis period have come from the abilityof the friundation to draw on our nerwork of international expert volunieers pioviding small but meaningful coniiibutions that have made a significant difference on the ground. South Africa and Eswatini had experienced ongoing issues with the supply of effective antr￿enoms leading to shortages. At the reouesi ol officials from the local regulatory authorities ISAHPRAI and local organisations. rhe Antivenom Foun¢Jation provided experts 10 compile and review the available evidence Yor alternatwe antwenoms. This led to the ernergencyapprovdl lundei section 211 of 2 8ntivenoms. Thanks to ihiswork in obtainingemergencyapproval. one of these 8ntivenoms was procured and extensNely used by I￿81 orginisaiions in Esw8tini. which in November 2024 r Kenya like rnany countries has a substantial burden of snakebites and unequal access to effective antivenoms. Through our ne￿Ork of contacts. IheAntivenom foundation was able to faciliiaie a 2of4 2411212024. 14:22 Firefox about:blank D¢w$*n En￿or*I0." &4D25F3W3Es47￿A29A-9￿￿28F72822 Annual repon 2311212024 ANTIVE"NOM donation o1600vials laproximaiiy l (K>-1sOtreatmentsi of antNenom byconnecting suppliers io the ministry of health in Baringo county. wth Logstical support foi the donation provided by MSF. Lebanon has long had issueswth antivenom availability and suitability. Workingwith roxicologists atthe American Universityof Beirut IAUBI. theAntwenoffl Foundation has fosteied a collaboration th antivenom experts atthe Universityofcosta Rica to develop an effective antivenom forthe Middle East and North African IMENAI region. This effon led to a new reformulated antivenom which is due ro enter phase 1 safety studies in Lebanon underthe supervision of AUB. FINIlNCI£lL REVIEI¥' RcN"icB' of financial P051tion The Antivenom Foundation is Siill a start-up charity in the process of setting up. it Iheieloie has not undertaken any substantialfundraisingor acti￿[leS thai incuTied anyexpense. In the process of establishingthe charitywe encountered substantial difficLJlties in opening a bank account, having been refused a bank account by a111he major banks. despite having duly followed their lengthy process. A number of grant applicaiionswere made.. however. these were all Unsuccessful. A modest sum of £157 was raise¢J. primarilyfrom on￿"ne donation-cashback" plattorms. The sums raised are noi sufticieni to undenake anyaciiwfies related to the primaryaim ol the charity to supply antiven0￿ and have therefore beerh held in reserve. Rescrvcs polia" To date the foundation has not raised any significant funds and does not incur any overheads so does not have a formal reserves policy. Should thi5 Posltion change in the future then the tiustees 11 develop a reserves policy as appropriate. Going concerns The current econornic enwronment has been chaliengingfor the charity sector. As a start-up charitythere are very limited opponunitiesio obiain grant funding, which are further diminished by our intern8tional o(Jrlook and focus on neglected diseases. Aniwenom is expenswe., SLJbs18ntial sums will Ihereloie need to be raised before (he loundaiion can stan ro lullil its primary objective ol providing aniivenom to Ihose in need. Noneiheless, the foundation does not currently Incur any expenses and provides a valuable nucleus that connects local oiginisation5 to experts. Despite the difficulties raising funds. the foundation is supported bydedicated volunteers who are in It for the longterm and prepared for a difficuli road ahead. The trustees are therefore not concerned about the abilityof the charity io continue. STRUCTURE, GOVERNANCE AND IIANAGE,IIENT The Antivenom Foundation is a Chaiitable Incoiporated Oiganisation ICIOI governed by constitution. Trustees are appointed for a term of 3years by majority resolution passed at a properly convened meeting of the charity trustees. In selecting indmduals for appointment a5 charity irusi¢es. the charityirustees must have regard 10 the skills. knowledge and experience needed for rhe effective adminisrraiion of the CIO_ 3of4 2411212024. 14:22 Firefox about:blank D¢wsww En￿or*I0.. fy4D25F3W3E>47￿A29A-9B￿26F Annual repon 2311212024 ANTIVE"NOM REFERENCE AND AD￿[INIST]LlTIVE DETAILS Antivenom Foundation IAVF) ReE: 1204543 Addre88 11 SpringGrove Godairning GU7 3SS Trustees Faisa Price Steven Swallow Alessia Cacioni ActNefrom Tefm 311812023 4 year5 311812023 3 Years 710112024 3years FUNDS HELD AS CLTSTODIAN TRUSTEES ON BEHALF OF OTHERS Not applicable DF.C.L.IRATI()NS The trustees declare that they have approved the trustees, report above. Trustee= Faisa Price Trustee: Steven Swallow Signed.. Signed: 1212312024 of4 2411212024. 14:22 Docusign Envelope ID: 5D6EE10E-7662-42DD-8163-C84342E9BA13 **Antivenom Foundation** **Antivenom Foundation 1204543 Receipts and payments accounts For the period** 31/8/2023 23/12/2024 **To from** ## **CC16a** ## **Section A Receipts and payments** |**A1 Receipts**|**Unrestricted**
**funds**
**to the nearest £**
**157**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**157**
**-**
**-**
**-**
**157**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**157**
**-**
**-**
**157**|**Restricted**
**funds**
**to the nearest £**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**|**Endowment**
**funds**
**to the nearest £**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**|**Total funds**
**to the nearest £**
**157**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**157**
**-**
**-**
**-**
**157**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**157**|**Total funds**
**to the nearest £**
**157**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**157**
**-**
**-**
**-**
**157**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**157**|**Last year**
**to the nearest £**| |---|---|---|---|---|---|---| |Donations|**157**|||||**-**| ||**-**|||||**-**| ||**-**|||||**-**| ||**-**|||||**-**| ||**-**|||||**-**| ||**-**|||||**-**| ||**-**|||||**-**| ||**-**|||||**-**| |**_Sub total_**_(Gross income for_
_AR)_|**157**|||||**-**| |||||||| |**A2 Asset and investment sales,**
**(see table).**||||||| ||**-**|||||| ||**-**
|||||**-**| |~~**_Sub total_**~~|**-**|||||**-**| |**_Total receipts_ **
**A3 Payments**||||||| |||||||**-**| |||||||| ||**-**|||||**-**| ||**-**|||||**-**| ||**-**|||||**-**| ||**-**|||||**-**| ||**-**|||||**-**| ||**-**|||||**-**| ||**-**|||||**-**| ||**-**|||||**-**| ||**-**|||||**-**| |**_Sub total_ **|**-**|||||**-**| |||||||| |**A4 Asset and investment**
**purchases, (see table)**||||||| ||**-**|||||| ||**-**|||||| |**_Sub total_ **|**-**|||||**-**| |**_Total payments_**
**_Net of receipts/(payments)_**
**A5 Transfers between funds**
**A6 Cash funds last year end**
**_Cash funds this year end_**||||||| |||||||**-**| |||||||| ||**157**|**-**|**-**|**157**||**-**| ||**-**|**-**|**-**|**-**||**-**| ||**-**|**-**|**-**|**-**||**-**| ||**157**|**-**|**-**|**157**||**-**| CCXX R1 accounts (SS) 23/12/2024 1 Docusign Envelope ID: 5D6EE10E-7662-42DD-8163-C84342E9BA13 |**Section B Statement of assets and liabilities at**|**Section B Statement of assets and liabilities at**|**the end of the period**|| |---|---|---|---| |**Categories**
Signed by one or two trustees on
behalf of all the trustees
**B5 Liabilities**
**B3 Investment assets**
**B2 Other monetary assets**
**B4 Assets retained for the**
**charity’s own use**
**B1 Cash funds**|**Details**
**Details**
**Details**
**Details**
**_Total cash funds_**
(agree balances with receipts and payments
account(s))
**Details**
Donations
Signature|**Unrestricted**
**funds**
**Restricted**
**funds**
**to nearest £**
**to nearest £**
**157**
**-**
**-**
**-**
**-**
**-**
**157**
**-**
OK
OK
**Unrestricted**
**funds**
**Restricted**
**funds**
**to nearest £**
**to nearest £**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**Fund to which**
**asset belongs**
**Cost (optional)**
**-**
**-**
**-**
**-**
**-**
**Fund to which**
**asset belongs**
**Cost (optional)**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**Fund to which**
**liability relates**
**Amount due**
**(optional)**
**-**
**-**
**-**
**-**
**-**
Print Name
Faisa Price|**Endowment**
**funds**
**to nearest £**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||OK| ||||**Endowment**
**funds**
**to nearest £**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**Current value**
**(optional)**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**Current value**
**(optional)**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**When due**
**(optional)**| ||||| ||||| ||||| ||||| ||||| ||||| ||||Date of
approval| |||Faisa Price|23/12/2024| ||||| CCXX R2 accounts (SS) 23/12/2024 2